AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Truist Securities Reiterates Hold Rating on Amgen (AMGN), 'Competition for OX40 in atopic dermatitis narrowing'
March 29, 2022 10:42 AM EDTTruist Securities analyst Robyn Karnauskas reiterated a Hold rating and $263.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Competition for OX40 in atopic dermatitis narrowing. This morning Sanofi (SNY;NR) highlighted their anti-OX40 ligand amlitelimab is a priority asset... More
